指南与共识冠心病心力衰竭与心肌病血脂与心血管预防

炎症与心血管疾病:2025 ACC科学声明解读

Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology.
指南 / 共识 · J Am Coll Cardiol · 2025-09-29

该科学声明更新了慢性低度炎症在CVD中的作用,重点涉及动脉粥样硬化、心肌梗死、心衰和心包炎。声明汇总了筛查、评估、风险评价、影像生物标志物、生活方式干预及抗炎治疗等方面的共识推荐。强调炎症与ASCVD的关联已具临床可操作性,但并非所有二级预防抗炎试验均成功,广泛推荐其他药物前需更多证据。

要点

  • hsCRP可预测他汀治疗患者的残余炎症风险及健康人群首发CVD风险。
  • LDL-C正常但hsCRP升高者,他汀治疗可显著降低首发主要CVD事件风险。
  • 抗炎治疗二级预防证据不一,广泛推荐其他药物前需更多试验支持。

核心结论

  • 炎症与动脉粥样硬化性CVD的关联已从探索性转为确凿且具临床可操作性。
  • hsCRP测量的残余炎症可预测他汀治疗患者的复发性事件。
  • 健康人群hsCRP升高提示更高风险,他汀可降低首发主要CVD事件。

研究设计与样本

  • 美国心脏病学会(ACC)科学声明,汇总炎症与CVD的更新认识及共识推荐。

主要发现

  • hsCRP测量的残余炎症在他汀治疗患者中仍强烈预测复发性事件。
  • 健康人群hsCRP升高且LDL-C正常时,他汀显著降低首发主要CVD事件风险。
  • 声明涵盖动脉粥样硬化、心肌梗死、心衰和心包炎的新研究证据。
  • 并非所有二级预防抗炎试验均成功,广泛推荐其他药物前需更多证据。
  • 炎症与关键生理系统的交互作用在成功试验中常未完全阐明。

关键数值与推荐

  • 使用高敏C反应蛋白(hsCRP)测量残余炎症并预测复发事件。
  • 健康人群hsCRP升高可识别他汀治疗获益的更高风险人群。
  • 声明汇总筛查、评估、影像生物标志物及抗炎治疗的共识推荐。

临床怎么用

  • 可使用hsCRP评估他汀治疗患者的残余炎症风险。
  • 对LDL-C正常但hsCRP升高者,考虑他汀治疗以降低首发CVD事件。
  • 抗炎治疗用于二级预防需基于成功试验证据,避免广泛推荐其他药物。

局限性

  • 并非所有二级预防抗炎试验均成功,其他药物广泛推荐证据不足。
  • 成功试验中炎症与关键生理系统的交互作用常未完全阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The crucial role of inflammation in the pathogenesis and clinical outcomes of cardiovascular disease (CVD) has recently gained increased attention. In particular, residual inflammation, measured with high-sensitivity C-reactive protein (hsCRP) remains strongly predictive of recurrent events, even in statin-treated patients. Similarly, elevated hsCRP in apparently healthy individuals identifies a higher-risk group in whom statin therapy significantly reduces the risk of first major CVD events even if LDL-cholesterol is normal. This report provides an updated understanding of the role of chronic, low-grade inflammation in CVD and highlights new seminal research findings, especially in atherosclerosis, myocardial infarction, heart failure, and pericarditis. Consensus recommendations are summarized for screening, evaluation, and CVD risk assessment; inflammatory biomarkers in cardiovascular imaging; inflammation inhibition in behavioral and lifestyle risks; and anti-inflammatory approaches in primary and secondary prevention as well as in heart failure and other CVDs. This report also addresses current challenges and future opportunities. For example, it cautions that not all trials of anti-inflammatory therapy in secondary prevention have been successful and such trial evidence is needed before broad recommendations for other agents can be made. Additionally, in successful trials, the interplay between inflammation and key physiological systems often remains incompletely examined. Another promising area of research is the role that novel special pro-resolving bioactive lipid molecules play in promoting the resolution of inflammation and CVD risk reduction. In aggregate, the evidence linking inflammation with atherosclerotic CVD is no longer exploratory but is compelling and clinically actionable. The time for taking action has now arrived.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Mensah GA, Arnold N, Prabhu SD, et al. Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology. J Am Coll Cardiol. 2025. PMID: 41020749. doi:10.1016/j.jacc.2025.08.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。